top of page

Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance and how the company leverages understandings from this to tackle human disease. On Thursday, Fauna signed a deal with Eli Lilly worth up to $494 million to collaborate on obesity targets.

Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page